Across TCGA pan-cancer cohorts, CLDN5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN5 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CLDN5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN5 expression acts as an unfavorable survival marker.

LIHC, SARC, and UCEC are the cancer types where CLDN5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.051	0.772	<.001	24	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CLDN5 tumor-vs-normal RNA expression · all CLDN5 data types